Contact: Executives-Edge.com Rayk@capmarketsmedia.com

Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Doug Murray, Chief Executive Officer at Auvik. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the specific industry challenges that...

Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Omer Itzhak, Vice President of Product at Cytactic. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the specific pain points in...

Tech Edge hosted a fireside chat on April 30 at RSAC 2025 in San Francisco with Dan Amiga, co-founder and Chief Technology Officer at Island. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the enterprise browser market...

Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Corey Still, Vice President of Strategic Alliances at Corero Network Security. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed which...

By Daniella Parra Vinson & Elkins represented Sunoco LP (NYSE: SUN) in a definitive agreement with Parkland Corp. (TSX: PKI) where Sunoco will acquire all outstanding shares of Parkland in a cash and equity transaction valued at approximately $9.1 billion,...

Tech Edge hosted a fireside chat on April 30 at Sysdig headquarters in San Francisco with Karen Walker, Chief Financial Officer. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the market trends driving increased investment in...

Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Seth Spergel, Managing Partner at Merlin Ventures. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why Merlin Ventures has focused...

By Karen Roman Recordati said it established its three-year financial targets for 2025-2027, with expected revenue of €3.0 to €3.2 billion for 2027 and EBITDA of €1.14 to €1.225 billion. The company’s strategy is driven by organic growth, its leadership,...

By Daniella Parra Araris Biotech AG  joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said. The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform...